摘要
[目的]评价美罗华联合CHOP方案治疗滤泡型NHL的临床效果及不良反应。[方法]第1天：美罗华375mg/m^2,600 mg静点;地塞米松15 mg静推;第2天：环磷酰胺750 mg/m^2,1.2 g静推;长春新碱1.4 mg/m^2,2mg静推;法玛新60 mg/m^2,110 mg静推;第2-5天：强的松100毫克口服。每21天1周期,连用7周期。[结果]完全缓解。毒副反应主要是骨髓抑制Ⅲ°、口腔炎Ⅲ°、便秘Ⅲ°、脱发Ⅱ°、恶心呕吐Ⅰ,°可耐受。[结论]美罗华联合CHOP方案治疗滤泡型NHL可获得较好疗效,毒副反应可以耐受,是一个较好的化疗方案。
[ Objective] To evaluate the results of combined Rituximab with CHOP in the chemotherapy of follicular lymphoma. [ Methods] A patient with follicular lymphoma received Rituximab 375mg/m^2 by intravenous infusion on the fifth day, Dexamethasone 15mg by intravenous on the first day,Cytoxan 750 mg/m^2 by intravenous on the second day,Vinblastine 1.4mg/m^2 by intravenous on the second day. Epirubicin Hydrochloride 60 mg/m^2 by intravenous on day2. Prednisone 100 mg by Poon the second day to the fifth day. The treatment was repeated every 21 days, up to 7 cycles. [ Results ] CR . The main toxicities were myelosuppression, oral inflammation, constipation,alopecia, nausea and other side effects. [ Conclusion ] A high response rate can be obtained in follicular lymphoma by CHOP plus Rituximab. It is a promising antitumor agent with tolerable toxicity.
出处
《大连医科大学学报》
CAS
2007年第4期412-413,共2页
Journal of Dalian Medical University
关键词
美罗华
化疗
滤泡型淋巴瘤
rituximab
chemotherapy
follicular lymphoma
